These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39533148)

  • 1. Investigating the Safety Profile of Fast-Track COVID-19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study.
    Kim HJ; Yoon JH; Lee KH
    Pharmacoepidemiol Drug Saf; 2024 Nov; 33(11):e70043. PubMed ID: 39533148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
    Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients.
    Mozaffari E; Chandak A; Ustianowski A; Rivera CG; Ahuja N; Jiang H; Berry M; Okulicz JF; Amin AN
    Clin Ther; 2024 Oct; 46(10):778-784. PubMed ID: 39244489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
    Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
    Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
    Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022.
    Bihan K; Lipszyc L; Lemaitre F; Dautriche A; Fédrizzi S; Atzenhoffer M; Vitores A; Page A; Lebrun-Vignes B
    Therapie; 2023; 78(5):531-547. PubMed ID: 37012153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
    Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.
    Hu JL; Wu JY; Xu S; Qian SY; Jiang C; Zheng GQ
    J Headache Pain; 2024 Oct; 25(1):169. PubMed ID: 39375581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
    Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure.
    Kamo M; Sogawa R; Shimanoe C
    In Vivo; 2024; 38(4):1841-1846. PubMed ID: 38936945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten.
    Yukselen Z; Raju AKV; Kumar PA; Ujjawal A; Dasari M; Parajuli S; Nakhla M; Bansal K; Ganatra S; Dani SS
    Am J Cardiovasc Drugs; 2024 Nov; 24(6):791-799. PubMed ID: 39164512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Zur M; Peselev T; Yanko S; Rotshild V; Matok I
    Antiviral Res; 2024 Jan; 221():105768. PubMed ID: 38056602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database.
    Hai L; Wu J; Xie Y
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70037. PubMed ID: 39420647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Yang Z; Tang K; Chen J
    Expert Opin Drug Saf; 2024 Nov; 23(11):1439-1446. PubMed ID: 39325652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients.
    Exquis N; Dionisi B; Samer CF; Rollason V; Curtin F; Zekry D; Graf C; Prendki V; Ing Lorenzini K
    Viruses; 2024 May; 16(6):. PubMed ID: 38932157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.